Pilot study of the feasibility of a double-blind, randomized, placebo-controlled localized area ultraviolet phototherapy trial methodology 1 
| INTRODUC TI ON
Localized ultraviolet (UV) phototherapy is an effective treatment for many inflammatory dermatoses. 1 Localized UV treatment modalities include excimer lasers, excimer non-laser devices, and non-excimer devices. 2 In order to delineate the efficacy of the different options, well-controlled clinical trials are critical. However, trials comparing the efficacy of phototherapy devices are often not blinded, leading to participation and expectancy biases. The purpose of this study is to test a methodology suitable for robust double-blind, randomized, placebo-controlled, localized area UV phototherapy intervention trials.
| ME THODS
Following Wake Forest School of Medicine institutional review board approval, 3 healthy volunteer participants were recruited, and informed consent was obtained before the start of the study.
Participants were excluded from the study if they had a history of non-response to UVB therapy, had received phototherapy in the past 4 weeks or topical therapy (other than emollients) in the past 2 weeks, had a history of a photosensitizing disorder, had a history of any immunocompromising disorder, or were pregnant. Each participant's back was partitioned into 3 sections denoted as A, B, and C ( Figure 1 ). The 3 sections were randomized to be covered with:
(A) a UV-opaque acrylic block (Polycast UF3, Sterling Industries), (B) a UV-transparent acrylic block (Polycast SUVT, Sterling Industries), or (C) no block. The UV-transparent and UV-opaque acrylic blocks (Polycast UF3 and Polycast SUVT, Sterling Industries, Shawnee, KS)
were visually identical (transparent to visible and infrared light), and the investigator was blinded as to which acrylic block was used at which site.
Using a template with six 1-cm squares on the participant's back, an increasing series of laser-generated fluencies of 100, 150, 200, 250, 300, and 350 mJ/cm 2 were administered using a xenon chloride excimer laser (XTRAC Ultra Plus, PhotoMedex Inc, Carlsbad, CA) to each of the 3 areas. The minimal erythemal dose (MED) of each of the interventions was visually measured 24 h following laser treatment. MED was defined as the minimal fluence capable of yielding a well-defined, macular area of pink erythema. 3 Since this was a within-subject design, the data was analyzed for mean differences in MED among the interventions using a randomized block in analysis of variance (ANOVA). Subjects were the blocking variable and pairwise comparisons of the mean MED scores were performed.
| RE SULTS
Three healthy screened subjects were recruited and completed the study. The median age was 26 years (range, 25-27) and 66% were male. No erythema developed in any of the 6 treatment sites in any of the 3 subjects in the area covered with the UV-opaque acrylic block (Table 1 ). In all 3 subjects, the area with the UV-transparent acrylic block and the area with no block yielded identical withinsubject MED readings (mean, 266.67 mJ/cm 2 ). No adverse effects were noted in any of the 3 groups.
| D ISCUSS I ON
To date, there are no double-blinded, randomized study designs comparing the efficacy of localized laser or phototherapy interventions. However, results of this study suggest the use of 2 identical appearing acrylic blocks, 1 UV-opaque, and 1 UV-transparent, may provide a suitable means for performing double-blinded phototherapy studies.
Limitations in the study design may have affected the findings.
MED visual readings were used as the primary outcome measure to determine if the use of a UV-transparent acrylic block affected the xenon chloride excimer laser-generated fluencies. MED visual readings were increased at an increment of 50 mJ/cm 2 , and while the uncovered and UV-transmitting acrylic covered areas yielded identical MED readings in all 3 subjects, the actual generated fluencies between the 2 interventions may have been different at an error of less than ±50 mJ/cm 2 . However, in clinical and research settings, increasing laser-generated fluencies of laser devices often use a series of doses given at 50 mJ/cm 2 intervals in the determination of the MED. 4 Future studies may consider using a spectrophotometer and evaluating fluency increments of less than 50 mJ/cm 2 , such as 25 mJ/cm 2 , as a more sensitive means of determining whether the UV-transmitting acrylic filter has a smaller effect on the transmitted dose.
This study provides feasibility on the use of a UV-opaque and UV-transparent acrylic block in the design of double-blind, randomized, placebo-controlled localized area phototherapy trials that can be used in future studies to demonstrate unequivocally the efficacy of localized UV phototherapy devices.
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